Understanding how cancer immunotherapy can lead to diabetes
Elucidating mechanisms of checkpoint inhibitor-induced diabetes
This study is looking into how cancer treatments, especially those that boost the immune system, can sometimes lead to diabetes, and it's aimed at helping patients who might experience this side effect by finding ways to prevent it.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10930958 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind diabetes that can occur as a side effect of cancer immunotherapy, specifically checkpoint inhibitors. The principal investigator, Dr. Ana Perdigoto, aims to identify how immune cells interact with pancreatic cells to cause this condition. By studying these immune-related adverse events, the research seeks to uncover potential therapeutic targets to mitigate these complications for patients undergoing cancer treatment. The work is conducted at Yale University, leveraging a collaborative environment and expert mentorship.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who are receiving checkpoint inhibitor therapies and may be at risk for developing diabetes.
Not a fit: Patients who are not undergoing cancer treatment or those who do not have a risk of developing diabetes from immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better management strategies for diabetes induced by cancer immunotherapy, improving patient quality of life.
How similar studies have performed: Previous research has shown that understanding immune-related adverse events can lead to significant advancements in managing complications from cancer therapies, indicating a promising avenue for this investigation.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Perdigoto, Ana Luisa Jordao — Yale University
- Study coordinator: Perdigoto, Ana Luisa Jordao
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.